patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug · antibody

save

ABRILADA

Marketedupdated 2mo ago

by $PFE PFIZER INC🔗 ChEMBL

Approved

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.

targets

Tumor necrosis factor

all catalysts(7)

approval · 7

News(1)

Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
stat · 2mo ago

brand

ABRILADA

trade names

Amgevita, Amsparity, Cyltezo, Halimatoz, Hefiya, Hulio

generic

ADALIMUMAB-AFZB

MOA

12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with ABRILADA may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab products exert their clinical effects is unknown. Adalimumab products also modulate biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1–2 × 10 -10 M).

phase

marketed

ABRILADA

targets

all catalysts(7)

News(1)

comments(0)

Report a data issue

🐶 often sniffed alongside